Geert D’Haens

ORCID: 0000-0003-2784-4046 · 2 papers in corpus

2024

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Inflammatory bowel diseases ·doi:10.1093/ibd/izae024

BackgroundMirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative col…

article 2020

Su1888 INTESTINAL ULTRASOUND THROUGHOUT PREGNANCY IN INFLAMMATORY BOWEL DISEASE PATIENTS, FEASIBILITY AND RELIABILITY OF A NON-INVASIVE CROSS-SECTIONAL IMAGING MODALITY

·doi:10.1016/s0016-5085(20)32415-x